Diligence memo · auto-generated · as of July 2, 2026

HCW Biologics Inc.

HCW Biologics Inc. looks fair against its niche peers and is quiet on financing cadence.

SourceRaising on rhythm with a 2.8× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

HCW Biologics Inc. operates in Biotechnology, based in MIRAMAR.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

HCW Biologics Inc. has raised $16M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.9M on 2024-11-20.

Most recent recorded round closed around 2024-11-20.

Valuation (modeled)modeled

Provath models HCW Biologics Inc. at approximately $30M (range $7.5M–$60M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.68× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Within the normal band (68% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 25 months.

Last raise 19 mo ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round stepped up 2.8× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 64% of Biotechnology peers (4293 compared).

Modeled value ranks above 35% of those peers.

Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..

Peoplefiled

13 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.